Patent ID: 6716411
Filing Date: 2004-04-06
Classification: A61K,A61P,G01N

Abstract:
A method for determining the therapeutic window of a purine or pyrimidine nucleotide synthesis inhibitor in inhibiting purine or pyrimidine nucleotide biosynthesis comprising the steps of:a) determining an efficacious dose of said nucleotide synthesis inhibitor in a mammal; b) administering said nucleotide synthesis inhibitor in said efficacious dose to said mammal; c) determining the concentration of said nucleotide synthesis inhibitor in the blood of said mammal; and d) determining whether said nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide wherein said shorter half-life is an indication of a wider therapeutic window of said purine or pyrimidine nucleotide synthesis inhibitor than N-(4-trifluoromethylphenyl)-2-3-hydroxycrotonamide in inhibiting purine or pyrimidine nucleotide biosynthesis.